DataMeds AI Registers 34.5M Shares for Resale — Potential 55% Dilution from Convertible Notes
MEDS has more than doubled off its 52-week low of $0.823 on light trading volume (0.1× avg).
Summary
DataMeds AI filed an amended S-1 to register 34.5 million shares for resale by holders of its May 2026 convertible notes and warrants. The filing quantifies potential dilution of 55.1% at a $3.81 conversion price, with the conversion price variable and tied to the market price.
Key Events · Financing and Capital Events · MEDS
-
34.5M Shares Registered for Resale
The S-1/A registers 34,462,057 shares for resale by selling stockholders, consisting of 1,282,143 previously issued shares, 21,300,295 shares issuable upon conversion of May 2026 Notes or Series A Preferred Stock, 8,298,225 shares issuable upon exercise of PIPE Warrants, and 3,581,394 shares issuable upon exercise of placement agent warrants.
-
55.1% Dilution at $3.81 Conversion Price
If all May 2026 Notes convert at the September 28, 2026 closing price of $3.81, approximately 5,546,670 shares would be issued, representing 55.1% dilution to existing stockholders. The conversion price is variable and tied to the market price, so a lower stock price would result in even greater dilution.
-
Variable Conversion Price Creates Downward Spiral Risk
The May 2026 Notes convert at the lesser of $6.00 or the closing price on the trading day before conversion, with a $1.00 floor. The filing warns that a declining stock price leads to more shares issued, which can further depress the price and encourage short selling.
-
Helomics Acquisition Adds $1.36M Convertible Note
The filing discloses the September 11, 2026 acquisition of Helomics for 636,328 shares plus a $1.36M convertible note with a $1.00 conversion price. The note automatically converts upon stockholder approval, adding another potential source of dilution.
Analysis · MEDS · Trade & Services
This S-1/A registers 34.5 million shares for resale by holders of the May 2026 convertible notes and warrants. The filing quantifies the dilution risk: if all notes convert at the September 28 closing price of $3.81, existing shareholders face approximately 55.1% dilution. The conversion price is variable and tied to the market price, so a falling stock price would trigger even greater dilution. The filing also discloses the Helomics acquisition and a $1.36M convertible note with a $1.00 conversion price, adding another layer of potential share issuance. Against the backdrop of a $26.1M Q2 loss, going concern doubt, and a Nasdaq equity deficiency deadline of October 12, 2026, this registration enables the selling stockholders to liquidate their positions, creating significant overhang on the stock.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDS was trading at $3.02 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $0.82 to $73.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.